Cancer drug Trodelvy's Long-Term safety checked in small study
NCT ID NCT04319198
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at the long-term safety of the drug sacituzumab govitecan (Trodelvy) in 25 people with metastatic solid tumors who were already benefiting from the treatment. Participants continued to receive the drug intravenously, and researchers tracked any side effects or lab abnormalities. The goal was to see how safe the drug is over a longer period.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sacituzumab govitecan (Trodelvy)
What this could lead to
If successful, this study could confirm that sacituzumab govitecan is safe for long-term use in people with metastatic solid tumors, supporting its continued use as a treatment option.
What could go wrong
This is a small, completed safety study with only 25 participants, so results may not apply to everyone. The drug can cause side effects, and the study does not test whether it works better than other treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baptist Health - Miami Cancer Institute
Miami, Florida, 33176, United States
-
CHU UCL NAMUR - Sainte Elisabeth
Namur, 5000, Belgium
-
Centre Leon Berard
Lyon, 69373, France
-
Christiana Care Health Services, Christiana Hospital
Newark, Delaware, 19718, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Florida Cancer Specialists & Research Institute
Fort Myers, Florida, 33905, United States
-
Illinois Cancer Specialists
Arlington Heights, Illinois, 60005, United States
-
Institut Bergonie
Bordeaux, 33076, France
-
Institut Claudius Regaud
Toulouse, 31059, France
-
Institut Jules Bordet
Brussels, 1000, Belgium
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
NEXT Oncology
San Antonio, Texas, 78229, United States
-
New York Cancer & Blood Specialists - Setauket Medical Oncology
Port Jefferson, New York, 11776, United States
-
Next Oncology
Austin, Texas, 78758, United States
-
Oncology Consultants,P.A.
Houston, Texas, 77024, United States
-
Rocky Mountain Cancer Center
Aurora, Colorado, 80012, United States
-
The University of Texas M.D. Anderson Cancer Center
Houston, Texas, 77030, United States
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15213, United States
-
University of California San Francisco
San Francisco, California, 94143, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of MD Greenebaum Comprehensive Cancer Center
Baltimore, Maryland, 21201, United States